- Home
- Applications
- europe
- potential ad therapeutic
Show results for
Refine by
Potential Ad Therapeutic Product Applications In Europe
5 applications found
The concept behind protein arrays is the immobilisation of sets of proteins, up to very large numbers, on solid supports, to perform miniaturised, multiplexed binding assays with a variety of potential ligands or interactants (see powerpoint presentation on right). HuProt v4 human proteome arrays as used at CPA comprise full length human proteins, many of which will retain their native conformation. HuProt arrays can be distinguished from arrays of peptides, used primarily to identify linear epitopes, or protein ...
ByCambridge Protein Arrays Ltd. (CPAP) based in Cambridge, UNITED KINGDOM
Natural killer (NK) cells have long been known to play a significant role in the body’s innate immune response. They were first described in the 1970s, but only in the last 15 years has significant progress been made in understanding the complexities and therapeutic potential these cells offer in helping fight cancer and other diseases. Today, we know that NK cells not only detect and identify malignant cancer cells, but they also induce cancer cell death and even help trigger a broader adaptive immune ...
ByKiadis Pharma NV based in Amsterdam, NETHERLANDS
Our platform delivers investigational medicinal products that contain diverse and viable communities of donor-derived microorganisms that target multiple functional pathways. We believe that this approach is superior to others being pursued and provides the company with numerous competitive advantages, including: de-risking of clinical programmes based on IMT precedence, accelerated clinical development and opportunities to discover second and third generation products through data generated from clinical ...
ByEnteroBiotix Ltd based in Glasgow, UNITED KINGDOM
We adapted an autologous ex-vivo gene therapy method to load the patient’s own TEMs precursors, that are hematopoietic stem and progenitor cells (HSPCs), with an immunotherapeutic transgene sequence. By re-introducing gene-modified HSPCs into the patient, we seek to take advantage of the self-renewing and multi-differentiation capability of HSPCs to enable durable and potentially long-term effects following a single ...
ByGenenta Science based in Milano, ITALY
Deliver the right cells to the patient on time. Maximize Functional Characterization of Your Precious T Cell Samples. The Opto™ Cell Therapy Development workflow accelerates the creation of better therapeutics by performing multiple functional assays across 1,000s of individual T cells in a matter of days. Deeply characterize, profile, and map your T cell populations at the single-cell level to directly link phenotype to gene ...
ByBruker Corporation based in Billerica, MASSACHUSETTS (USA)